Glenmark Pharmaceuticals plans to launch over 10 products in FY16

26 Aug 2015 Evaluate

Glenmark Pharmaceuticals (GPL) is planning to launch 10-12 new products in the domestic market during the current financial year (2015-16) and hopes to report a growth of 18-20 percent. The company wants to increase its focus on the Indian market across four key areas, including dermatology, diabetes, cardiology and respiratory segments. The company derives about 26% of its revenues from the India, which is its second largest market.

GPL is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2014). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).

Glenmark Pharma Share Price

1540.70 -52.20 (-3.28%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.